RBM3 and ovarian cancer: Moreover, the reduced cytotoxic effect of cisplatin in RBM3 silenced ovarian cancer cells has been reported to be mainly attributed to cell cycle alterations rather than to apoptosis, as cisplatin-induced G2/M-phase arrest was less evident in siRBM3-treated cells compared to control, whereas no significant changes in the percentage of apoptotic cells could be observed.